MetaCap

Immunic (IMUX) vs Satellos Bioscience (MSLE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immunic (IMUX) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 1.9% versus a loss of 5.3%. Over five years, MSLE leads with a -58.5% price change compared with -91.9% for IMUX. Satellos Bioscience is the larger company by market cap ($120.5 million vs $111.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMUX+1.90%MSLE-5.33%
+155%+60%-34%
Nov 21, 20251 yearNov 20, 2026
IMUX-92.54%MSLE-53.27%
+52%-26%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMUX versus MSLE key metrics
MetricIMUXMSLE
Share price$6.99$5.68
Market cap$111.01M$120.51M
1-day change-5.41%-2.07%
YTD return+30.90%-3.40%
1-year return+1.90%-5.33%
5-year return-91.88%-58.48%
EPS (TTM)$-3.53$-2.12
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-97.17M$-24.87M
52-week high$17.43$13.40
52-week low$5.06$5.44
Distance from 52-week high-59.90%-57.60%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+508.73%+325.53%
Average volume343.44K51.19K
Shares outstanding15.88M21.22M
Employees10018
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Immunic

IMUX stock →

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Satellos Bioscience

MSLE stock →

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.

Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees

IMUX vs MSLE FAQ

Which is bigger, Immunic or Satellos Bioscience?

Satellos Bioscience (MSLE) is larger, with a market capitalization of $120.51M compared with $111.01M for Immunic (IMUX).

Which stock has performed better over the past year, IMUX or MSLE?

IMUX returned +1.90% over the past 12 months, compared with -5.33% for MSLE (price return, excluding dividends). Past performance does not predict future results.

Are Immunic and Satellos Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons